The metabolic effects of endocrine therapy in postmenopausal women with oestrogen-receptor-positive breast cancer

Not Applicable

Completed

• Conditions: cardiovascular disease; Breast cancer; Menopause; oestradiol depletion; Cardiovascular - Coronary heart disease; Metabolic and Endocrine - Metabolic disorders; Cancer - Breast

• Registration Number: ACTRN12619001046190
• Lead Sponsor: The Department of Medicine, Austin Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-07-24
• Study Completion: 2022-10-07
• Last Update Posted: 31 October 2022

Recruitment & Eligibility

• Status: Completed
• Sex: Female
• Target Recruitment: 105

Inclusion Criteria

Non-metastatic breast cancer
-Postmenopausal
-Aged 50-85yrs
-To commence endocrine therapy treatment intended for at least 12 months
-ECOG less than or equal to 1
-Ability to consent for study and comply with the study protocol requirements

Exclusion Criteria

-Previous exposure to endocrine therapy (greater than 8 weeks prior to recruitment)
-If endocrine therapy stops or changes
-Established type 2 diabetes mellitus
-Continuous glucocorticoid therapy for less than or equal to 2 weeks within 6 months of study
-Hormone replacement therapy within 3 months of study
-Any disease which is likely to lead to serious illness or death within the study period

Study & Design

• Study Type: Observational
• Study Design: Not specified